Neogenix Oncology
Great Neck
About Neogenix Oncology
Neogenix Oncology is a clinical stage bio-therapeutics company that focuses on developing novel therapeutic and diagnostic products for the treatment of pancreatic, colon, lung, prostate, and various other cancers. Its primary product, NEO-101, is a novel Phase II monoclonal antibody for colorectal and pancreatic cancer indications. Neogenix Oncology’s product pipeline also includes NEO-201 and NEO-301, which are preclinical monoclonal antibodies for the treatment of pancreatic and colorectal cancers. The company also has a research collaboration agreement with San Raffaele-Pisana to study the expression of tumor-specific biomarkers using NEO-101, NEO-201, and NEO-301 therapeutic programs. Headquartered in Great Neck, New York, Neogenix Oncology was founded in 2003.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $15.8M
- Last round: Series Unknown (Sep 2010)
- Website: neogenixoncology.com
- Phone: 516-482-1200
Industries & Categories
Biotechnology, Health Care, Medical, Oncology
Canonical: https://fsome.com/organization/neogenix-oncology-1731682 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.